Immunovant, Inc.

NasdaqGS:IMVT Stock Report

Market Cap: US$8.2b

Immunovant Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:IMVT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
08 Jul 26SellUS$47,702Christopher Van TuylIndividual1,206US$39.99
08 Jul 26SellUS$137,925Jay StoutIndividual3,487US$39.99
08 Jul 26SellUS$80,532Melanie GloriaIndividual2,036US$39.99
26 Jun 26SellUS$1,532,309Jay StoutIndividual40,000US$38.94
26 Jun 26SellUS$678,604Melanie GloriaIndividual17,714US$38.95
18 Jun 26SellUS$93,217Christopher Van TuylIndividual2,634US$35.39
28 May 26SellUS$850,746Andrew FromkinIndividual25,350US$33.56
20 May 26SellUS$101,072Melanie GloriaIndividual3,115US$32.95
23 Apr 26SellUS$763,011Tiago GiraoIndividual25,760US$29.62
23 Apr 26SellUS$81,573Jay StoutIndividual2,754US$29.62
08 Apr 26SellUS$216,567Melanie GloriaIndividual8,722US$24.83
08 Apr 26SellUS$128,247Christopher Van TuylIndividual5,165US$24.83
18 Mar 26SellUS$71,839Christopher Van TuylIndividual2,877US$24.97
25 Feb 26SellUS$90,184Melanie GloriaIndividual3,238US$28.90
21 Jan 26SellUS$51,461Jay StoutIndividual1,977US$26.03
07 Jan 26SellUS$31,914Jay StoutIndividual1,203US$26.92
18 Dec 25SellUS$290,943Christopher Van TuylIndividual10,813US$27.38
12 Dec 25BuyUS$349,999,986Roivant Sciences Ltd.Company16,666,666US$21.00
20 Nov 25SellUS$298,237Melanie GloriaIndividual12,626US$23.97
22 Oct 25SellUS$49,383Michael GeffnerIndividual2,595US$19.03
22 Oct 25SellUS$47,956Jay StoutIndividual2,520US$19.03
08 Oct 25SellUS$20,734Michael GeffnerIndividual1,272US$16.30
08 Oct 25SellUS$25,836Jay StoutIndividual1,585US$16.30
23 Jul 25SellUS$43,288Michael GeffnerIndividual2,385US$18.15
23 Jul 25SellUS$50,911Jay StoutIndividual2,805US$18.15

Insider Trading Volume

Insider Buying: IMVT insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of IMVT?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,719,7470.762%
VC/PE Firms11,526,9715.11%
Institutions99,084,90543.9%
Public Companies113,317,00750.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20%.

Top Shareholders

Top 25 shareholders own 100.72% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
55.2%
Roivant Sciences Ltd.
113,317,007US$4.5b0%no data
8.25%
FMR LLC
16,936,250US$672.5m-0.25%0.03%
5.61%
Deep Track Capital, LP
11,526,971US$457.7m0%6.75%
3.2%
BlackRock, Inc.
6,574,497US$261.1m8.52%no data
2.66%
Baker Bros. Advisors LP
5,457,881US$216.7m0%1.07%
2.21%
State Street Global Advisors, Inc.
4,537,929US$180.2m19.8%no data
2.17%
TCG Crossover Management, LLC
4,457,988US$177.0m168%4.3%
1.93%
T. Rowe Price Group, Inc.
3,952,467US$157.0m-33.6%0.01%
1.8%
Vanguard Portfolio Management, LLC
3,704,905US$147.1m0%0.01%
1.76%
Vanguard Capital Management, LLC
3,620,050US$143.8m0%no data
1.74%
Armistice Capital LLC
3,564,916US$141.6m-38%3.57%
1.56%
Two Seas Capital LP
3,201,962US$127.1m11.7%4.91%
1.56%
Jennison Associates LLC
3,196,705US$126.9m356%0.07%
1.55%
RTW Investments, LP
3,177,849US$126.2m0%1.05%
1.3%
ADAR1 Capital Management, LLC
2,679,010US$106.4m7.98%5.34%
1.28%
Alpine Global Management, LLC
2,636,925US$104.7m0.39%17.62%
1.28%
Morgan Stanley Investment Management Inc.
2,617,956US$104.0m-18.2%0.09%
1.02%
Geode Capital Management, LLC
2,092,102US$83.1m12.6%no data
0.96%
Woodline Partners LP
1,975,869US$78.5m0%0.26%
0.78%
Perceptive Advisors LLC
1,597,383US$63.4m-19.9%1.11%
0.75%
Farallon Capital Management, L.L.C.
1,546,000US$61.4m12,800%0.3%
0.58%
The Goldman Sachs Group, Inc.
1,188,924US$47.2m15.3%0.01%
0.57%
Aberdeen Group Plc
1,160,762US$46.1m-1.97%0.02%
0.52%
Logos Global Management, L.P.
1,075,000US$42.7m-21.8%1.94%
0.48%
Morgan Stanley
985,941US$39.2m-28.7%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/13 07:54
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immunovant, Inc. is covered by 23 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
William PickeringBernstein
Dina RamadaneBofA Global Research